Bright Minds Pb Ratio Over Time

DRUG Stock  USD 35.00  0.67  1.88%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bright Minds Performance and Bright Minds Correlation.
  
The current PB Ratio is estimated to decrease to 1.32.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.45)
Return On Assets
(0.29)
Return On Equity
(0.52)
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Pb Ratio Analysis

Compare Bright Minds Biosciences and related stocks such as Revelation Biosciences, Zura Bio Limited, and Phio Pharmaceuticals Corp Pb Ratio Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Dividend YieldRoic
Payables TurnoverRoe
Return On Tangible AssetsEarnings Yield
Receivables TurnoverShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Capital Employed
Fixed Asset TurnoverReturn On Assets
Asset TurnoverReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
REVB(390.5 K)(390.5 K)(390.5 K)(390.5 K)(390.5 K)(390.5 K)(390.5 K)(390.5 K)(390.5 K)(390.5 K)429(16.2 K)54.52418.24310.00270.0028
ZURA26.680226.680226.680226.680226.680226.680226.680226.680226.680226.680226.680226.6802(3.896)2.42422.792.65
PHIO(3.0E-4)(3.0E-4)(2.0322)6.886912.79772.80480.44376.83740.17080.75320.9470.58440.46770.20440.240.22
ZVSA(18.7349)(18.7349)(18.7349)(18.7349)(18.7349)(18.7349)(18.7349)(18.7349)(18.7349)(18.7349)(18.7349)(12.8261)0.14240.07920.07130.0749
RNAZ(1.8 K)(1.8 K)(1.8 K)(1.8 K)(1.8 K)(1.8 K)(1.8 K)(1.8 K)(1.8 K)(806)(327)34.611987.720423.724321.3522.42
PYXS(158)(158)(158)(158)(158)(158)(158)(158)(158)(158)(28.9473)1.35270.27520.57140.75510.79
ELEV(46.2815)(46.2815)(46.2815)(46.2815)(46.2815)(46.2815)(46.2815)(46.2815)(46.2815)(46.2815)(11.7764)0.99290.45080.33390.53680.56
IMMX(3.3969)(3.3969)(3.3969)(3.3969)(3.3969)(3.3969)(3.3969)(3.3969)(3.3969)(3.3969)(6.0309)2.61782.3027.31486.586.91
ADTX(1.1 B)(1.1 B)(1.1 B)(1.1 B)(1.1 B)(1.1 B)(1.1 B)(1.1 B)(32.3 M)(22.9 M)6.1 M2.5 MM312.1 K280.9 K295 K
DRMA(26.099)(26.099)(26.099)(26.099)(26.099)(26.099)(26.099)(26.099)(26.099)(26.099)(23.0907)21.507411.25830.27930.00130.0014
UNCY(32.9322)(32.9322)(32.9322)(32.9322)(32.9322)(32.9322)(32.9322)(32.9322)(32.9322)(47.6528)(28.5415)1.8741(17.4481)(5.5901)(5.03)(5.28)

Bright Minds Biosciences and related stocks such as Revelation Biosciences, Zura Bio Limited, and Phio Pharmaceuticals Corp Pb Ratio description

My Equities

My Current Equities and Potential Positions

Bright Minds Biosciences
DRUG
ClassificationPharmaceutical Products
LocationBritish Columbia; Canada
ExchangeNASDAQ Exchange
USD 35.0
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:
Check out Bright Minds Performance and Bright Minds Correlation.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Bright Minds technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Bright Minds technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Bright Minds trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...